What is Biolife Solutions Inc's earnings per share (EPS)?

Biolife Solutions Inc (BLFS) reported diluted earnings per share of -$0.10 for fiscal year 2025. This represents a 77.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Biolife Solutions Inc Financials

BLFS

FY2025 annual

Revenue $96.2M +28.9% YoY

Net Income -$4.6M +77.2% YoY

EPS (Diluted) -$0.10 +77.3% YoY

Free Cash Flow $10.6M +104.4% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Biolife Solutions Inc (BLFS) reported $96.2M in revenue for fiscal year 2025, up 28.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BLFS FY2025 2026-08-29

Revenue scale returned in FY2025, but cash generation improved faster than operating profitability while reported leverage moved toward zero.

Revenue reached $96.2M in FY2025 while operating margin worsened from FY2024 to FY2025, indicating that added volume brought expense or mix pressure rather than clear fixed-cost absorption. Meanwhile, operating cash flow of $20.1M exceeded the $4.6M net loss, so cash conversion was positive even as accounting earnings remained negative; that gap points to noncash charges and/or working-capital effects.

Gross margin remained above 60.0% in FY2024 and FY2025, but its compression alongside a more negative operating margin shows that growth was not purely scale-driven. SG&A and R&D reached $45.5M and $7.6M, respectively, leaving substantial gross economics without corresponding operating profit.

Reported long-term debt fell from $5.0M in FY2024 to $0 in FY2025, making the balance sheet lightly debt-funded. The current ratio reached 5.9x while investing cash flow swung to an outflow of $71.5M, so strong short-term coverage coexisted with substantial capital deployment.

Financial Health Signals

Financial Health Score 70/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Biolife Solutions Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Safe

29.88

Biolife Solutions Inc scores 29.88, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.7B) relative to total liabilities ($34.0M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

6/9

Biolife Solutions Inc passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed

N/A

Biolife Solutions Inc reported a net loss of $4.6M while generating $20.1M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$96.2M

YoY+28.9%

5Y CAGR+14.9%

10Y CAGR+31.0%

Biolife Solutions Inc generated $96.2M in revenue in fiscal year 2025. This represents an increase of 28.9% from the prior year.

EBITDA

-$14.3M

YoY-2200.9%

Biolife Solutions Inc's EBITDA was -$14.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 2200.9% from the prior year.

Net Income

-$4.6M

YoY+77.2%

Biolife Solutions Inc reported -$4.6M in net income in fiscal year 2025. This represents an increase of 77.2% from the prior year.

EPS (Diluted)

-$0.10

YoY+77.3%

Biolife Solutions Inc earned -$0.10 per diluted share (EPS) in fiscal year 2025. This represents an increase of 77.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$10.6M

YoY+104.4%

5Y CAGR+17.8%

Biolife Solutions Inc generated $10.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 104.4% from the prior year.

Cash & Debt

$33.0M

YoY-63.9%

5Y CAGR-18.2%

10Y CAGR+31.3%

Biolife Solutions Inc held $33.0M in cash against $0 in long-term debt as of fiscal year 2025.

Shares Outstanding

48M

YoY+2.8%

5Y CAGR+7.7%

10Y CAGR+14.5%

Biolife Solutions Inc had 48M shares outstanding in fiscal year 2025. This represents an increase of 2.8% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

64.6%

YoY-2.6pp

Biolife Solutions Inc's gross margin was 64.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 2.6 percentage points from the prior year.

Operating Margin

-17.3%

YoY-11.3pp

5Y CAGR-4.3pp

10Y CAGR+60.5pp

Biolife Solutions Inc's operating margin was -17.3% in fiscal year 2025, reflecting core business profitability. This is down 11.3 percentage points from the prior year.

Net Margin

-4.8%

YoY+22.3pp

5Y CAGR-8.9pp

10Y CAGR+60.6pp

Biolife Solutions Inc's net profit margin was -4.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 22.3 percentage points from the prior year.

Return on Equity

-1.2%

YoY+4.5pp

5Y CAGR-2.2pp

Biolife Solutions Inc's ROE was -1.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 4.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$7.6M

YoY+59.3%

5Y CAGR+2.4%

10Y CAGR+18.6%

Biolife Solutions Inc invested $7.6M in research and development in fiscal year 2025. This represents an increase of 59.3% from the prior year.

Capital Expenditures

$9.5M

YoY+193.7%

5Y CAGR+37.0%

10Y CAGR+53.1%

Biolife Solutions Inc invested $9.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 193.7% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

BLFS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BLFS quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	$106.7M	$96.2M+28.9%	$74.6M+9.7%	$68.0M-10.8%	$76.2M-36.0%	$119.2M+147.8%	$48.1M+75.7%	$27.4M+38.6%	$19.7M+79.1%	$11.0M+34.0%	$8.2M+27.6%	$6.4M+4.2%	$6.2M-30.8%	$8.9M+58.0%	$5.7M+105.3%	$2.8M
Cost of Revenue	N/A	$34.1M+38.9%	$24.6M-8.0%	$26.7M	N/A	N/A	N/A	$8.8M+40.9%	$6.2M+45.4%	$4.3M+24.0%	$3.4M+30.9%	$2.6M-16.5%	$3.2M-39.2%	$5.2M+53.9%	$3.4M+148.6%	$1.4M
Gross Profit	N/A	$62.1M+24.0%	$50.1M+21.2%	$41.3M	N/A	N/A	N/A	$18.6M+37.6%	$13.5M+100.5%	$6.7M+41.2%	$4.8M+25.3%	$3.8M+25.7%	$3.0M-19.3%	$3.8M+64.1%	$2.3M+63.4%	$1.4M
R&D Expenses	$9.8M	$7.6M+59.3%	$4.8M-13.9%	$5.5M-36.4%	$8.7M-26.6%	$11.8M+75.9%	$6.7M+112.1%	$3.2M+144.1%	$1.3M+8.8%	$1.2M-41.2%	$2.0M+47.1%	$1.4M+58.3%	$871K+78.6%	$488K+5.2%	$464K-10.2%	$516K
SG&A Expenses	$45.8M	$45.5M+12.0%	$40.6M-5.1%	$42.8M+28.7%	$33.3M-1.2%	$33.7M+120.4%	$15.3M+71.7%	$8.9M+49.5%	$6.0M+31.5%	$4.5M-1.5%	$4.6M-5.7%	$4.9M+22.6%	$4.0M+46.0%	$2.7M+26.4%	$2.2M+17.6%	$1.8M
Operating Income	$1.7M	-$16.6M-270.8%	-$4.5M+74.0%	-$17.2M-190.5%	-$5.9M+83.2%	-$35.2M-463.4%	-$6.2M-2736.8%	-$220K-106.0%	$3.7M+446.8%	-$1.1M+78.2%	-$4.9M+3.3%	-$5.0M-60.0%	-$3.1M-998.9%	-$285K+69.7%	-$942K+22.1%	-$1.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$5K0.0%	$5K-97.4%	$190K+90.0%	$100K	$0-100.0%	$177K-76.1%	$742K+1.2%	$733K+9.3%	$671K
Income Tax	-$42.4M	$49K+228.9%	-$38K+40.6%	-$64K+98.8%	-$5.2M+74.0%	-$20.1M-516.4%	-$3.3M-111.8%	-$1.5M	N/A	$0	$0	$0	$0	$0	$0	N/A
Net Income	$58.0M	-$4.6M+77.2%	-$20.2M+70.3%	-$68.0M+51.4%	-$139.8M-1469.4%	-$8.9M-549.2%	$2.0M+219.7%	-$1.7M+93.4%	-$25.0M-894.2%	-$2.5M+63.4%	-$6.9M-63.2%	-$4.2M-31.0%	-$3.2M-196.8%	-$1.1M+34.7%	-$1.7M+15.2%	-$2.0M
EPS (Diluted)	$1.17	-$0.10+77.3%	-$0.44+71.6%	-$1.55+52.3%	-$3.25-1313.0%	-$0.23-283.3%	-$0.06+33.3%	-$0.09+94.2%	-$1.56-642.9%	-$0.21	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$28.5M+3.5%	$27.5M+21.4%	$22.7M-19.3%	$28.1M+19.7%	$23.4M+6.3%	$22.1M+46.0%	$15.1M-29.4%	$21.4M
Cost of Revenue	$10.2M+1.7%	$10.0M	N/A	N/A	$8.2M+13.1%	$7.3M	N/A	N/A
Gross Profit	$18.3M+4.5%	$17.5M	N/A	N/A	$15.2M+2.9%	$14.8M	N/A	N/A
R&D Expenses	$3.0M+11.6%	$2.6M+82.4%	$1.5M-46.4%	$2.7M+37.9%	$2.0M+36.6%	$1.4M+15.5%	-$1.2M-34.2%	$1.9M
SG&A Expenses	$10.7M-12.4%	$12.2M+12.4%	$10.9M-10.0%	$12.1M+7.5%	$11.2M-1.0%	$11.4M-2.0%	$11.6M+24.2%	$9.3M
Operating Income	$1.7M+6181.5%	$27K-75.9%	$112K+225.8%	-$89K+99.4%	-$16.1M-3131.7%	-$499K-192.1%	$542K+229.7%	-$418K
Income Tax	-$42.4M-68408.1%	$62K+135.8%	-$173K-311.0%	$82K-34.9%	$126K+800.0%	$14K-41.7%	$24K+130.0%	-$80K
Net Income	$45.1M+3703.0%	$1.2M-89.3%	$11.1M+1682.6%	$621K+103.9%	-$15.8M-3435.3%	-$448K-103.6%	$12.5M+831.6%	-$1.7M
EPS (Diluted)	$0.91+4450.0%	$0.02-91.3%	$0.23+2200.0%	$0.01+103.0%	-$0.33	$0.00-100.0%	$0.27+775.0%	-$0.04

Not reported in any period shown, so not listed: Interest Expense.

BLFS Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BLFS quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$405.9M+1.6%	$399.5M-3.2%	$412.7M-8.3%	$450.2M-18.8%	$554.3M+136.0%	$234.8M+153.0%	$92.8M+104.1%	$45.5M+274.4%	$12.1M+53.2%	$7.9M-35.9%	$12.4M-23.0%	$16.1M+379.3%	$3.4M+5.8%	$3.2M+90.7%	$1.7M
Current Assets	$136.6M-8.2%	$148.8M+23.3%	$120.6M-12.9%	$138.5M+9.8%	$126.1M+9.9%	$114.7M+375.7%	$24.1M-35.8%	$37.6M+278.2%	$9.9M+114.6%	$4.6M-33.6%	$7.0M-42.7%	$12.2M+547.7%	$1.9M+15.4%	$1.6M+40.3%	$1.2M
Cash & Equivalents	$33.0M-63.9%	$91.5M+228.1%	$27.9M+43.5%	$19.4M-72.2%	$69.9M-22.7%	$90.4M+1302.0%	$6.4M-79.0%	$30.7M+360.1%	$6.7M+373.9%	$1.4M-35.3%	$2.2M-14.4%	$2.5M+1524.6%	$156K-20.5%	$196K+1065.1%	$17K
Inventory	$30.2M+3.9%	$29.0M+6.8%	$27.2M-22.2%	$34.9M+23.1%	$28.3M+144.3%	$11.6M+5.7%	$11.0M+212.7%	$3.5M+90.0%	$1.8M+5.1%	$1.8M-4.2%	$1.8M+90.1%	$965K+129.3%	$421K-35.9%	$656K+29.7%	$506K
Accounts Receivable	$8.0M-6.2%	$8.5M+7.3%	$7.9M-76.7%	$33.9M+46.2%	$23.2M+190.0%	$8.0M+49.8%	$5.3M+75.5%	$3.0M+198.2%	$1.0M-14.5%	$1.2M+28.4%	$929K+3.1%	$902K-10.7%	$1.0M+68.2%	$600K+9.7%	$547K
Goodwill	$208.6M0.0%	$208.6M-1.8%	$212.3M-5.5%	$224.7M+284.5%	$58.4M0.0%	$58.4M+73.8%	$33.6M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$34.0M-32.8%	$50.6M-32.6%	$75.1M-12.8%	$86.0M+12.9%	$76.2M+157.7%	$29.6M-40.1%	$49.4M+60.1%	$30.8M+42.3%	$21.7M+355.3%	$4.8M+89.6%	$2.5M+17.5%	$2.1M-87.1%	$16.6M+6.2%	$15.7M+21.9%	$12.8M
Current Liabilities	$23.0M-29.8%	$32.7M-22.4%	$42.2M-5.4%	$44.6M+4.4%	$42.7M+174.2%	$15.6M+103.1%	$7.7M+295.5%	$1.9M+28.2%	$1.5M+33.5%	$1.1M-34.3%	$1.7M+36.8%	$1.3M-22.5%	$1.6M+19.2%	$1.4M+135.7%	$579K
Long-Term Debt	$0-100.0%	$5.0M-71.5%	$17.6M-26.2%	$23.8M+274.5%	$6.4M+869.9%	$655K+4938.5%	$13K	N/A	N/A	$4.3M	N/A	N/A	N/A	N/A	N/A
Total Equity	$371.9M+6.6%	$348.9M+3.3%	$337.7M-7.3%	$364.2M-23.8%	$478.0M+133.8%	$204.4M+371.9%	$43.3M+196.1%	$14.6M+253.5%	-$9.5M-401.0%	$3.2M-62.8%	$8.5M-38.9%	$13.9M+205.0%	-$13.3M-6.3%	-$12.5M-11.7%	-$11.2M
Retained Earnings	-$339.7M-1.4%	-$335.1M-6.4%	-$314.9M-27.5%	-$246.9M-130.5%	-$107.1M-10.0%	-$97.4M-197.2%	$100.2M+201.8%	-$98.4M-33.0%	-$74.0M-3.9%	-$71.2M-10.7%	-$64.3M-7.0%	-$60.1M-5.7%	-$56.9M-1.9%	-$55.8M-3.1%	-$54.2M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$447.5M+11.6%	$400.9M-1.2%	$405.9M+3.5%	$392.1M+1.3%	$387.2M-2.0%	$395.1M-1.1%	$399.5M+4.7%	$381.7M
Current Assets	$135.2M+1.5%	$133.2M-2.4%	$136.6M+7.9%	$126.6M+0.9%	$125.4M-4.3%	$131.1M-11.9%	$148.8M+66.4%	$89.4M
Cash & Equivalents	$24.0M+5.1%	$22.8M-30.9%	$33.0M+12.1%	$29.5M-7.6%	$31.9M-52.3%	$66.9M-26.9%	$91.5M+281.8%	$24.0M
Inventory	$35.6M+8.4%	$32.8M+8.9%	$30.2M+8.4%	$27.8M+0.5%	$27.7M+0.4%	$27.6M-5.0%	$29.0M-9.8%	$32.2M
Accounts Receivable	$10.7M-18.4%	$13.1M+64.2%	$8.0M-26.6%	$10.8M+7.8%	$10.1M+9.7%	$9.2M+8.2%	$8.5M-52.7%	$17.9M
Goodwill	$208.6M0.0%	$208.6M0.0%	$208.6M-1.8%	$212.3M0.0%	$212.3M0.0%	$212.3M+1.8%	$208.6M-7.2%	$224.7M
Total Liabilities	$27.5M-4.1%	$28.7M-15.6%	$34.0M-11.3%	$38.3M-4.3%	$40.1M-5.7%	$42.5M-15.9%	$50.6M-10.0%	$56.2M
Current Liabilities	$13.9M-23.6%	$18.3M-20.6%	$23.0M-15.4%	$27.1M-4.1%	$28.3M+2.1%	$27.7M-15.3%	$32.7M+1.8%	$32.2M
Long-Term Debt	$0-100.0%	$2.5M	$0	$0	$0-100.0%	$2.5M-50.0%	$5.0M-36.1%	$7.8M
Total Equity	$420.0M+12.8%	$372.2M+0.1%	$371.9M+5.1%	$353.7M+1.9%	$347.2M-1.6%	$352.6M+1.1%	$348.9M+7.2%	$325.5M
Retained Earnings	-$293.4M+13.3%	-$338.5M+0.3%	-$339.7M+3.2%	-$350.8M+0.2%	-$351.4M-4.7%	-$335.5M-0.1%	-$335.1M+3.6%	-$347.6M

BLFS Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BLFS quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	$16.9M	$20.1M+138.6%	$8.4M+167.5%	-$12.5M-47.2%	-$8.5M-84.8%	-$4.6M-169.1%	$6.6M+447.8%	$1.2M-48.3%	$2.3M+288.1%	$605K+114.0%	-$4.3M+13.0%	-$5.0M-57.3%	-$3.2M-2265.9%	$146K-82.9%	$855K+186.4%	-$990K
Capital Expenditures	N/A	$9.5M+193.7%	$3.2M-49.4%	$6.4M-38.6%	$10.4M+23.9%	$8.4M+327.6%	$2.0M+190.5%	$675K+35.0%	$500K+247.2%	$144K+0.3%	$144K+7.1%	$134K-77.3%	$590K+149.2%	$237K-79.5%	$1.2M+1131.4%	$94K
Free Cash Flow	N/A	$10.6M+104.4%	$5.2M+127.6%	-$18.9M0.0%	-$18.9M-45.4%	-$13.0M-377.1%	$4.7M+770.6%	$538K-70.9%	$1.8M+300.9%	$461K+110.3%	-$4.5M+12.5%	-$5.1M-36.1%	-$3.8M-4038.4%	-$91K+69.5%	-$297K+72.6%	-$1.1M
Investing Cash Flow	-$8.2M	-$71.5M-222.7%	$58.3M+226.8%	$17.8M+130.7%	-$58.1M-340.5%	-$13.2M+46.6%	-$24.7M+8.5%	-$27.0M-315.7%	-$6.5M-4413.9%	-$144K-136.7%	$393K-90.7%	$4.2M+152.1%	-$8.1M-3337.3%	-$237K+79.4%	-$1.2M-1158.1%	-$91K
Financing Cash Flow	-$16.5M	-$10.9M-61.0%	-$6.8M-164.0%	$10.6M-35.1%	$16.3M+687.3%	-$2.8M-102.7%	$102.1M+6295.9%	$1.6M-94.3%	$28.1M+486.9%	$4.8M+51.4%	$3.2M+758.8%	$369K-97.3%	$13.7M+27011.3%	$50K-89.4%	$475K-56.6%	$1.1M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$6.3M+1392.9%	-$491K-110.0%	$4.9M-19.5%	$6.1M-17.2%	$7.4M+326.6%	$1.7M+5.0%	$1.6M-65.7%	$4.8M
Capital Expenditures	$1.0M+524.6%	$167K	N/A	N/A	$1.7M+896.0%	$175K	N/A	N/A
Free Cash Flow	$5.3M+906.2%	-$658K	N/A	N/A	$5.6M+262.4%	$1.6M	N/A	N/A
Investing Cash Flow	-$1.6M+13.7%	-$1.8M-260.9%	$1.1M+119.1%	-$6.0M+84.9%	-$39.5M-45.5%	-$27.2M-136.9%	$73.6M+4480.5%	-$1.7M
Financing Cash Flow	-$3.6M+54.5%	-$7.9M-216.3%	-$2.5M+2.4%	-$2.6M+11.1%	-$2.9M+3.8%	-$3.0M+26.8%	-$4.1M-292.5%	-$1.0M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

BLFS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

BLFS quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	64.6%-2.6pp	67.1%+6.4pp	60.8%	N/A	N/A	N/A	68.0%-0.5pp	68.5%+7.3pp	61.2%+3.1pp	58.1%-1.1pp	59.2%+10.1pp	49.0%+7.0pp	42.0%+1.6pp	40.5%-10.4pp	50.9%
Operating Margin	-17.3%-11.3pp	-6.0%+19.3pp	-25.3%-17.5pp	-7.8%+21.7pp	-29.5%-16.5pp	-13.0%-12.2pp	-0.8%-19.4pp	18.6%+28.1pp	-9.6%+49.4pp	-59.0%+18.8pp	-77.8%-27.2pp	-50.6%-47.5pp	-3.2%+13.5pp	-16.6%+27.2pp	-43.9%
Net Margin	-4.8%+22.3pp	-27.0%+72.9pp	-100.0%	-183.4%	-7.5%-11.6pp	4.1%+10.2pp	-6.0%	-126.7%	-22.8%+60.8pp	-83.6%-18.2pp	-65.3%-13.4pp	-52.0%-39.9pp	-12.1%+17.2pp	-29.3%+41.6pp	-70.9%
Return on Equity	-1.2%+4.5pp	-5.8%+14.4pp	-20.1%+18.3pp	-38.4%-36.5pp	-1.9%-2.8pp	1.0%+4.8pp	-3.8%+167.1pp	-170.9%	N/A	-217.1%-167.6pp	-49.5%-26.4pp	-23.1%	N/A	N/A	N/A
Return on Assets	-1.1%+3.9pp	-5.1%+11.4pp	-16.5%+14.6pp	-31.1%-29.4pp	-1.6%-2.5pp	0.8%+2.6pp	-1.8%+53.2pp	-55.0%-34.3pp	-20.7%+66.0pp	-86.7%-52.7pp	-34.1%-14.1pp	-20.0%+12.3pp	-32.3%+20.0pp	-52.4%+65.4pp	-117.7%
Current Ratio	5.94+1.4x	4.54+1.7x	2.86-0.2x	3.11+0.2x	2.95-4.4x	7.37+4.2x	3.14-16.2x	19.37+12.8x	6.56+2.5x	4.080.0x	4.04-5.6x	9.64+8.5x	1.150.0x	1.19-0.8x	2.00
Debt-to-Equity	0.000.0x	0.010.0x	0.050.0x	0.07+0.1x	0.010.0x	0.000.0x	0.00-2.1x	2.11	N/A	1.34+1.0x	0.29+0.1x	0.15	N/A	N/A	N/A
FCF Margin	11.1%+4.1pp	7.0%+34.7pp	-27.8%-3.0pp	-24.8%-13.9pp	-10.9%-20.6pp	9.7%+7.8pp	2.0%-7.4pp	9.4%+5.2pp	4.2%+58.5pp	-54.3%+24.9pp	-79.2%-18.6pp	-60.6%-59.6pp	-1.0%+4.2pp	-5.2%+34.0pp	-39.3%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	64.2%+0.6pp	63.6%	N/A	N/A	65.0%-2.1pp	67.1%	N/A	N/A
Operating Margin	6.0%+5.9pp	0.1%-0.4pp	0.5%+0.8pp	-0.3%+68.5pp	-68.8%-66.5pp	-2.3%-5.8pp	3.6%+5.5pp	-1.9%
Net Margin	158.4%	4.3%-44.5pp	48.9%+46.6pp	2.2%+69.8pp	-67.6%-65.5pp	-2.0%-84.5pp	82.5%+90.4pp	-8.0%
Return on Equity	10.7%+10.4pp	0.3%-2.7pp	3.0%+2.8pp	0.2%+4.7pp	-4.6%-4.4pp	-0.1%-3.7pp	3.6%+4.1pp	-0.5%
Return on Assets	10.1%+9.8pp	0.3%-2.4pp	2.7%+2.6pp	0.2%+4.3pp	-4.1%-4.0pp	-0.1%-3.2pp	3.1%+3.6pp	-0.4%
Current Ratio	9.69+2.4x	7.30+1.4x	5.94+1.3x	4.66+0.2x	4.43-0.3x	4.73+0.2x	4.54+1.8x	2.78
Debt-to-Equity	0.000.0x	0.010.0x	0.000.0x	0.000.0x	0.000.0x	0.010.0x	0.010.0x	0.02
FCF Margin	18.6%+21.0pp	-2.4%	N/A	N/A	24.0%+17.0pp	7.0%	N/A	N/A

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.

Similar Companies

Staar Surg STAA

$1.1B

Azenta Inc AZTA

$1.4B

KESTRA MED TECHNOLOGIES LTD KMTS

$1.5B

Pulse Biosciences Inc PLSE

$3.6B

Embecta Corp EMBC

$291.2M

Where Biolife Solutions Inc Ranks

Frequently Asked Questions

What is Biolife Solutions Inc's annual revenue?

Biolife Solutions Inc (BLFS) reported $96.2M in total revenue for fiscal year 2025. This represents a 28.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Biolife Solutions Inc's revenue growing?

Biolife Solutions Inc (BLFS) revenue grew by 28.9% year-over-year, from $74.6M to $96.2M in fiscal year 2025.

Is Biolife Solutions Inc profitable?

No, Biolife Solutions Inc (BLFS) reported a net income of -$4.6M in fiscal year 2025, with a net profit margin of -4.8%.

What is Biolife Solutions Inc's EBITDA?

Biolife Solutions Inc (BLFS) had EBITDA of -$14.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Biolife Solutions Inc have?

As of fiscal year 2025, Biolife Solutions Inc (BLFS) had $33.0M in cash and equivalents against $0 in long-term debt.

What is Biolife Solutions Inc's gross margin?

Biolife Solutions Inc (BLFS) had a gross margin of 64.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Biolife Solutions Inc's operating margin?

Biolife Solutions Inc (BLFS) had an operating margin of -17.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Biolife Solutions Inc's net profit margin?

Biolife Solutions Inc (BLFS) had a net profit margin of -4.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Biolife Solutions Inc's return on equity (ROE)?

Biolife Solutions Inc (BLFS) has a return on equity of -1.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Biolife Solutions Inc's free cash flow?

Biolife Solutions Inc (BLFS) generated $10.6M in free cash flow during fiscal year 2025. This represents a 104.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Biolife Solutions Inc's operating cash flow?

Biolife Solutions Inc (BLFS) generated $20.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Biolife Solutions Inc's total assets?

Biolife Solutions Inc (BLFS) had $405.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Biolife Solutions Inc's capital expenditures?

Biolife Solutions Inc (BLFS) invested $9.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Biolife Solutions Inc spend on research and development?

Biolife Solutions Inc (BLFS) invested $7.6M in research and development during fiscal year 2025.

How many shares does Biolife Solutions Inc have outstanding?

Biolife Solutions Inc (BLFS) had 48M shares outstanding as of fiscal year 2025.

What is Biolife Solutions Inc's current ratio?

Biolife Solutions Inc (BLFS) had a current ratio of 5.94 as of fiscal year 2025, which is generally considered healthy.

What is Biolife Solutions Inc's debt-to-equity ratio?

Biolife Solutions Inc (BLFS) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Biolife Solutions Inc's return on assets (ROA)?

Biolife Solutions Inc (BLFS) had a return on assets of -1.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Biolife Solutions Inc's Altman Z-Score?

Biolife Solutions Inc (BLFS) has an Altman Z-Score of 29.88, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Biolife Solutions Inc's Piotroski F-Score?

Biolife Solutions Inc (BLFS) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Biolife Solutions Inc's earnings high quality?

Biolife Solutions Inc (BLFS) reported a net loss of $4.6M while generating $20.1M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Biolife Solutions Inc?

Biolife Solutions Inc (BLFS) scores 70 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.